中国实用儿科杂志2026，Vol.41Issue(5)：353-362,10.DOI:10.19538/j.ek2026050601
基于暂时连接技术的长效生长激素临床应用专家指导意见
Clinical application of long-acting growth hormone based on transient conjugation technology:an expert perspective
摘要
Abstract
Growth hormone deficiency(GHD)is one of the leading endocrine causes of short stature in children and adolescents.Exogenous supplementation with recombinant human growth hormone(rhGH)is currently the main treatment option.While daily rhGH is clinically effective,long-term daily injections pose a substantial treatment burden and compliance challenges on both patients and caregivers.In recent years,long-acting growth hormone(LAGH)products(weekly administration)have become available,substantially reducing dosing frequency and thereby improving compliance.However,LAGH products based on different long-acting technologies vary markedly in molecular structure,drug properties,mechanism of action,pharmacokinetics/pharmacodynamics,clinical application and dosing regimens,as well as in safety monitoring requirements.Clinical experience in these products remains limited,and standardized guidance is lacking.Transient conjugation technology is an innovative technology for prolonging the duration of growth hormone;it has been widely used clinically in the United States and Europe,but its application experience and related research in China remain relatively limited.To optimize treatment strategies for GHD and enhance patients' treatment experience,we have developed this expert guidance on the clinical application of LAGH based on transient conjugation technology.This expert guidance addresses the developmental background of LAGH,outlines transient conjugation technology,provides an evidence-based interpretation of lonapegsomatropin(a LAGH developed using this technology),and offers specific recommendations on clinical application.关键词
生长激素缺乏症/长效生长激素/暂时连接技术/指导意见Key words
growth hormone deficiency/long-acting growth hormone/transient conjugation technology/standardization分类
医药卫生引用本文复制引用
中国医师协会儿科医师分会内分泌遗传代谢学组,罗小平..基于暂时连接技术的长效生长激素临床应用专家指导意见[J].中国实用儿科杂志,2026,41(5):353-362,10.基金项目
国家重点研发计划项目(2023YFC2706300) （2023YFC2706300）
